Roche (OTCQX:RHHBY) and Spark Therapeutics (NASDAQ:ONCE) have announced another extension of the Swiss drugmaker’s $4.3B takeover offer for the U.S. gene therapy specialist as regulatory reviews in the U.S. and Britain continue.
The offer for Spark shares now runs to Sept. 3, Roche said, adding terms and conditions are unchanged.
“The parties remain committed to the transaction and are working cooperatively and expeditiously with the Federal Trade Commission and UK Competition and Markets Authority.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.